ADC Control Human IgG1-vcMMAF is an antibody-drug conjugate (ADC) that combines a human IgG1 monoclonal antibody with the cytotoxic drug vcMMAF (monomethyl auristatin F). It is used as a control in ADC studies to help identify nonspecific effects. The vcMMAF payload targets and kills cancer cells by disrupting microtubule function.
Key Features:
- Isotype Control: The human IgG1 antibody does not target specific antigens, so any effects observed are from the payload.
- Cytotoxic Payload: vcMMAF inhibits microtubule function, leading to cancer cell death.
- Cleavable Linker: The linker releases the payload at the target site, reducing side effects.
- Human IgG1 Backbone: The antibody provides consistency in experiments.
Applications:
- Control in ADC Studies: Used as a negative control to distinguish between specific and nonspecific effects in ADC research.
- Mechanistic Research: Helps study how ADCs work, including their ability to kill cancer cells.
- Preclinical Development: Serves as a model to refine ADC components before clinical trials.
- Safety Profiling: Assesses off-target effects and improves ADC protocols.
Storage and Handling:
- Storage: Keep at -20°C, away from light and moisture.
- Handling: Follow standard lab precautions.
This ADC consists of a Human IgG1 kappa antibody, an isotype control, and a drug-linker conjugate with MC-Val-Cit-PAB-MMAF (vcMMAF).
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.